Current overview of personalized medicine in neurodegenerative diseases
DOI:
https://doi.org/10.63618/omd/ssjm/v2/n1/42Keywords:
personalized medicine, neurodegenerative diseases, biomarkers, targeted therapies, artificial intelligenceAbstract
Neurodegenerative diseases constitute a growing challenge for public health due to their clinical and biological complexity, as well as the absence of effective curative treatments. This article provides a critical and updated review on the current state of personalized medicine applied to these pathologies, emphasizing its potential to optimize diagnosis, prognosis and therapies by integrating biomarkers, genetic profiling and omics technologies together with artificial intelligence. A systematic analysis of the relevant scientific literature of the last decade was performed, selecting studies that address scientific advances, technological, ethical and economic challenges associated with clinical implementation. The results highlight significant advances in the identification of specific biomarkers, targeted therapies and predictive models based on artificial intelligence, although important barriers persist such as technological limitations, the need for specialized training, ethical concerns about privacy and high costs. It is concluded that the consolidation of personalized medicine in neurodegenerative diseases requires a multidisciplinary and comprehensive approach to overcome these challenges and ensure its accessibility and clinical efficacy.
Downloads
References
Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J., & Singleton, A. B. (2020). Genetics of Parkinson’s disease: An introspection of its journey towards precision medicine. Neurobiology of Disease, 137, 104782. https://doi.org/10.1016/j.nbd.2020.104782
Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. The New England Journal of Medicine, 372(9), 793–795. https://doi.org/10.1056/NEJMp1500523
De Strooper, B., & Karran, E. (2016). The Cellular Phase of Alzheimer's Disease. Cell, 164(4), 603–615. https://doi.org/10.1016/j.cell.2015.12.056
DeVos, S. L., Miller, T. M., & Gendron, T. F. (2017). Genetic therapies for neurodegenerative diseases. Annual Review of Pharmacology and Toxicology, 57, 441–465.
Frost, B., & Diamond, M. I. (2009). Prion-like mechanisms in neurodegenerative diseases. Nature Reviews Neuroscience, 11(3), 155–159. https://doi.org/10.1038/nrn2786
Garattini, L., & Curto, A. (2019). Personalized medicine: Can we afford it? Health Policy, 123(8), 722–726.
Hampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., ... & Lista, S. (2017). A precision medicine initiative for Alzheimer’s disease: The road ahead to biomarker-guided integrative disease modeling. Climacteric, 21(3), 190–202. https://doi.org/10.1080/13697137.2017.1287866
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019). Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 15(10), 565–581. https://doi.org/10.1038/s41582-019-0244-7
Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., ... & Silverberg, N. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Kumar, S., Sattar, F., & Kumar, V. (2021). Challenges in the clinical implementation of genomics and precision medicine. Genes, 12(6), 820.
Kwon, D., Ryu, J., & Kang, H. (2020). Precision medicine and the evolving role of biomarkers in neurodegenerative diseases. Experimental & Molecular Medicine, 52(6), 923–937.
Li, R., Chen, W., & Liu, H. (2021). Integrating multi-omics data by machine learning for personalized medicine in neurodegenerative diseases. Briefings in Bioinformatics, 22(6), bbab334.
Miller, K., Noseworthy, J., & Ginsburg, G. S. (2020). Infrastructure requirements for precision medicine. Clinical Pharmacology & Therapeutics, 107(4), 837–846.
O'Connor, C., Flicek, P., & Soranzo, N. (2020). Bioinformatics training and education: From theory to practice. Briefings in Bioinformatics, 21(2), 420–429. https://doi.org/10.1093/bib/bby091
Phillips, K. A., Van Bebber, S., & Issa, A. M. (2020). Economic considerations for personalized medicine in neurodegenerative diseases. Annual Review of Pharmacology and Toxicology, 60, 263–282.
Pritchard, D., Adamson, J., & Bhatt, A. (2019). Policy development for genomic medicine implementation: A review of initiatives and frameworks. Public Health Genomics, 22(1-2), 38–45.
Robinson, J. O., Buchanan, A., & Sugarman, J. (2019). Ethics of personalized medicine: Considerations in genetic counseling and testing. In R. P. Meisel & D. H. Rehmann (Eds.), Ethical and Legal Issues in Personalized Medicine (pp. 47–64).
Ross, C. A., Tabrizi, S. J., & Wild, E. J. (2019). Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 15(8), 409–
Santos, M., Morais, C., & Teixeira, A. L. (2021). The role of multi-omics in understanding neurodegenerative diseases: A path towards personalized medicine. Frontiers in Neuroscience, 15, 664746.
Shabani, M., Borry, P., & Prainsack, B. (2020). Governance of genetic data: Challenges and opportunities. Human Genetics, 139(7), 877–889.
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., ... & Rosas, H. D. (2019). Targeting huntingtin expression in patients with Huntington’s disease. The New England Journal of Medicine, 380(24), 2307–2316. https://doi.org/10.1056/NEJMoa1900907
Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
Valarezo-Bravo, O. F., Samaniego-Rojas, N. del C., Jara-Galdeman, G., Córdova Neira, K., & García Riofrío, J. C. (2023). Diagnóstico situacional y caracterización del perfil epidemiológico de las zonas de intervención e influencia del proyecto ProSalud frontera sur, cantones Huaquillas y Macará. Editorial Grupo AEA. https://doi.org/10.55813/egaea.l.2022.17
Vallejo-López, A. B., Ramírez-Amaya, J., Kou-Guzmán, J., Valdez-Aguagallo, F. R., & Ramírez- Morán, L. D. (2023). Enfermedades Respiratorias del Siglo XXI. Editorial Grupo AEA. https://doi.org/10.55813/egaea.l.2022.36
Villemagne, V. L., Dore, V., & Burnham, S. C. (2018). Imaging biomarkers for neurodegenerative diseases. Nature Reviews Neurology, 14(11), 653–666.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Herrera-Sánchez, Priscila Jaqueline , López -Cudco, Leidy Liceth (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
: